Sökresultat
Nordic Webinar on Malignant Melanoma
…aly INGE MARIE SVANE – Herlev – Gentofte Hospital, Denmark Agenda 16:30 Welcome and introduction – MD. PHD. MARTA NYAKAS AND – MD. PHD. ANNA WINGE MAIN, NO 16:40 Targeted therapies for BRAF–mutated advanced melanoma – efficacy and safety, clinical aspects and PK/PD profiles – PROFESSOR CAROLINE ROBERT, FR 17:10 The DAMMED report – The Danish Melanoma Registry – MD. PHD. EVA ELLEBÆK, DK 17:25 BREAK 17:40 Targeted therapy/IO Clinical cases and AE ma…
Treatment of head and neck cancer with PD-1 inhibitors – practical experiences and clinical evidence
…a number of clinical trials into new treatments. More information…
AstraZeneca & Daiichi Sankyo’s Enhertu godkänd i USA
…g conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo. The first tumour-agnostic approval of a HER2-directed therapy and ADC by the Food and Drug Administration (FDA) was based on results from the subgroup of patients with HER2-positive IHC 3+ tumours in each of the DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02 Phase II trials. Funda Meric-Bernstam, MD, Chair of Inves…
2nd Nordic CAR T Symposium
8th October 2020, 16:00–18:00 We are pleased to welcome you to the 2nd Nordic CAR T symposium. This year’s symposia will focus on the Nordic and European experience with CAR T, followed by insights on the underlying mechanism of CRS (cytokine release syndrome). This year the meeting will be fully digital and broadcasted live via link. Online attendees will be able to ask questions via the webinar platform. Please use the link below to register or…
CAR T-cell therapy makes its mark in CLL
…ts who received at least 2 prior lines of treatment, including a BTK inhibitor and a BCL-2 inhibitor. The approval was supported by findings from the phase 1/2 TRANSCEND CLL 004 study (NCT03331198) which showed patients treated with liso-cel (n = 65) achieved a complete response (CR) rate of 20% (95% CI, 11.1%- 31.8%). Notably, the median duration of response (DOR) was not reached (NR; 95% CI, 15 months-NR) at the data cutoff; the 12- and 18-month…